Ensysce Financial Statements From 2010 to 2024
| ENSC Stock | USD 0.54 0.03 5.26% |
Gross Profit -1.2 M | Market Capitalization 4.2 M | Revenue 2.2 M | Earnings Share (4.69) | Quarterly Revenue Growth (0.64) |
Ensysce Biosciences Total Revenue |
|
Check Ensysce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ensysce main balance sheet or income statement drivers, such as Tax Provision of 373.2 K, Interest Income of 93.6 K or Interest Expense of 432.8 K, as well as many exotic indicators such as Price To Sales Ratio of 1.02, Dividend Yield of 0.0051 or Days Sales Outstanding of 15.17. Ensysce financial statements analysis is a perfect complement when working with Ensysce Biosciences Valuation or Volatility modules.
Ensysce | Select Account or Indicator |
Ensysce Biosciences Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ensysce Biosciences Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ensysce Biosciences Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ensysce Biosciences Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ensysce Fundamental Market Drivers
| Cash And Short Term Investments | 1.1 M |
Ensysce Upcoming Events
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About Ensysce Biosciences Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Ensysce Biosciences income statement, its balance sheet, and the statement of cash flows. Ensysce Biosciences investors use historical funamental indicators, such as Ensysce Biosciences's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ensysce Biosciences investors may use each financial statement separately, they are all related. The changes in Ensysce Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ensysce Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ensysce Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ensysce Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 143.1 K | 127.2 K | |
| Total Revenue | 2.2 M | 2.2 M | |
| Cost Of Revenue | 22.8 M | 24 M | |
| Stock Based Compensation To Revenue | 0.39 | 0.37 | |
| Sales General And Administrative To Revenue | 2.40 | 3.22 | |
| Research And Ddevelopement To Revenue | 3.40 | 2.50 | |
| Capex To Revenue | 0.00 | 0.00 | |
| Revenue Per Share | 0.99 | 0.94 | |
| Ebit Per Revenue | (4.81) | (5.05) |
Pair Trading with Ensysce Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ensysce Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ensysce Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Ensysce Stock
| 0.85 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
| 0.84 | CNTA | Centessa Pharmaceuticals Downward Rally | PairCorr |
| 0.79 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.78 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.74 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to Ensysce Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ensysce Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ensysce Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ensysce Biosciences to buy it.
The correlation of Ensysce Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ensysce Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ensysce Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ensysce Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Ensysce Biosciences Correlation against competitors. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Ensysce Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.69) | Revenue Per Share 0.985 | Quarterly Revenue Growth (0.64) | Return On Assets (1.56) | Return On Equity (13.20) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.